Double maintains 2 strategies that include ABUS - Arbutus Biopharma Corp.
Current Value
$3.501 Year Return
Current Value
$3.501 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -29.38% | $153.01M | 0.85% |
TAIL | -28.52% | $107.77M | 0.59% |
BTAL | -17.12% | $298.87M | 1.43% |
UGA | -12.27% | $72.57M | 0.97% |
TPMN | -11.32% | $30.67M | 0.65% |
FTSD | -10.68% | $228.13M | 0.25% |
KCCA | -9.63% | $93.93M | 0.87% |
DBE | -9.04% | $48.80M | 0.77% |
ULST | -8.64% | $663.99M | 0.2% |
USL | -8.45% | $40.41M | 0.85% |
IVOL | -8.33% | $358.39M | 1.02% |
BNO | -7.79% | $87.69M | 1% |
OILK | -7.44% | $66.67M | 0.69% |
USO | -7.23% | $916.52M | 0.6% |
WEAT | -6.90% | $121.10M | 0.28% |
TFLO | -4.48% | $6.97B | 0.15% |
PDBC | -4.42% | $4.49B | 0.59% |
DBC | -4.26% | $1.19B | 0.87% |
COMT | -4.21% | $611.21M | 0.48% |
GBIL | -4.19% | $6.05B | 0.12% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DFDV | -15.89% | $380.05M | +2,345.35% | 0.00% |
FMTO | -12.88% | $5.10K | -99.92% | 0.00% |
MCK | -8.28% | $89.80B | +22.74% | 0.39% |
OCFT | -7.24% | $263.44M | +287.03% | 0.00% |
BPT | -6.11% | $13.72M | -72.13% | 0.00% |
HUSA | -4.99% | $8.56M | -56.67% | 0.00% |
LITB | -4.85% | $21.77M | -74.81% | 0.00% |
X | -4.56% | $12.11B | +43.61% | 0.37% |
K | -4.49% | $28.31B | +38.89% | 2.82% |
FUBO | -3.76% | $1.15B | +169.60% | 0.00% |
UUU | -3.76% | $7.36M | +96.30% | 0.00% |
MVO | -3.59% | $66.70M | -36.89% | 21.27% |
CLLS | -3.40% | $103.07M | -40.92% | 0.00% |
VHC | -3.26% | $37.77M | +135.71% | 0.00% |
SYPR | -2.59% | $44.35M | +2.66% | 0.00% |
MKTX | -2.52% | $8.44B | +11.89% | 1.32% |
GORV | -2.16% | $27.34M | -93.15% | 0.00% |
DRD | -1.67% | $1.21B | +68.55% | 1.94% |
CMTL | -1.61% | $64.23M | +3.07% | 0.00% |
BTCT | -1.53% | $21.81M | +56.22% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OXBR | -0.03% | $12.50M | -25.00% | 0.00% |
AIFU | 0.06% | $3.36B | 0.00% | 0.00% |
LPTH | -0.08% | $123.12M | +133.33% | 0.00% |
CYD | -0.15% | $718.48M | +121.39% | 1.85% |
AQB | -0.21% | $3.52M | -50.00% | 0.00% |
TK | -0.27% | $700.24M | +3.86% | 0.00% |
CALM | 0.46% | $4.94B | +58.23% | 7.23% |
CCEC | 0.49% | $1.02B | +3.91% | 2.79% |
ZCMD | -0.52% | $26.26M | -13.33% | 0.00% |
VRCA | 0.64% | $57.62M | -92.74% | 0.00% |
GFI | -0.71% | $21.79B | +53.72% | 2.21% |
RLMD | -0.74% | $25.44M | -74.70% | 0.00% |
NEUE | 0.75% | $60.80M | +26.11% | 0.00% |
CNR | -0.80% | $3.76B | -27.75% | 0.99% |
DADA | 0.80% | $513.15M | +32.00% | 0.00% |
CNK | -0.82% | $3.70B | +79.80% | 0.50% |
BTU | 0.85% | $1.68B | -39.96% | 2.27% |
VSA | 0.91% | $8.67M | -17.07% | 0.00% |
RLX | 0.96% | $1.98B | +19.13% | 0.46% |
PRPO | -1.03% | $16.74M | +87.63% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 53.07% | $4.89B | 0.35% |
IBB | 52.18% | $5.23B | 0.45% |
BBH | 49.56% | $334.99M | 0.35% |
FBT | 47.33% | $1.05B | 0.54% |
PBE | 47.03% | $229.19M | 0.58% |
GNOM | 45.93% | $44.34M | 0.5% |
XPH | 45.70% | $153.36M | 0.35% |
PINK | 45.15% | $131.18M | 0.5% |
KBWY | 44.91% | $220.89M | 0.35% |
FHLC | 43.44% | $2.45B | 0.084% |
FXH | 43.41% | $915.23M | 0.62% |
BBHY | 43.28% | $445.50M | 0.07% |
VHT | 43.12% | $15.31B | 0.09% |
SCYB | 42.83% | $1.11B | 0.03% |
USHY | 42.71% | $22.91B | 0.08% |
DFGR | 42.26% | $2.49B | 0.22% |
IBHG | 42.17% | $288.05M | 0.35% |
RWO | 42.07% | $1.12B | 0.5% |
HYLB | 41.97% | $3.81B | 0.05% |
IYH | 41.69% | $2.77B | 0.39% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IDYA | 46.43% | $1.92B | -44.38% | 0.00% |
DNLI | 44.48% | $2.21B | -29.48% | 0.00% |
IMVT | 43.65% | $2.76B | -36.82% | 0.00% |
KRYS | 41.39% | $4.03B | -23.27% | 0.00% |
IQV | 41.16% | $27.48B | -26.96% | 0.00% |
UNIT | 40.33% | $1.03B | +33.76% | 3.63% |
ROIV | 40.12% | $7.67B | +4.16% | 0.00% |
FRT | 39.62% | $8.32B | -4.35% | 4.56% |
ATXS | 39.57% | $326.75M | -37.61% | 0.00% |
BDTX | 39.49% | $134.76M | -62.02% | 0.00% |
IONS | 39.39% | $5.76B | -12.80% | 0.00% |
MGTX | 39.29% | $520.77M | +38.17% | 0.00% |
ESS | 39.24% | $18.43B | +5.43% | 3.43% |
COGT | 39.06% | $826.59M | -19.69% | 0.00% |
KW | 39.01% | $926.56M | -31.56% | 7.23% |
TECH | 38.70% | $8.08B | -33.45% | 0.62% |
IMNM | 38.66% | $825.75M | -40.69% | 0.00% |
SYRE | 38.65% | $1.09B | -51.35% | 0.00% |
AVB | 38.57% | $29.40B | +3.91% | 3.29% |
CIGI | 38.55% | $6.53B | +15.65% | 0.23% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UUP | -0.01% | $209.44M | 0.77% |
UNG | 0.07% | $372.51M | 1.06% |
CLIP | 0.32% | $1.50B | 0.07% |
CORN | -0.43% | $47.42M | 0.2% |
SHV | 0.46% | $20.36B | 0.15% |
TBLL | 0.89% | $2.26B | 0.08% |
UDN | 1.15% | $145.23M | 0.78% |
XONE | -1.31% | $634.70M | 0.03% |
FXE | -1.74% | $547.46M | 0.4% |
KRBN | 2.19% | $161.71M | 0.85% |
AGZD | -2.23% | $110.64M | 0.23% |
USDU | -2.29% | $165.88M | 0.5% |
FTGC | 2.61% | $2.44B | 0.98% |
USCI | 2.71% | $236.67M | 1.07% |
BIL | -2.81% | $44.07B | 0.1356% |
ASHR | 3.03% | $1.97B | 0.65% |
LDUR | 3.09% | $913.73M | 0.5% |
CANE | -3.26% | $10.08M | 0.29% |
GSG | -3.28% | $923.28M | 0.75% |
DBO | -3.29% | $209.14M | 0.77% |
SeekingAlpha
Tourlite Fund, LP returned â4.6% for the First Quarter of 2025. Click here to read the full fund letter.
SeekingAlpha
abrdn Life Sciences Investors Q1 2025 Commentary
Yahoo
Arbutus (ABUS) delivered earnings and revenue surprises of -44.44% and 10.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
WARMINSTER, Pa. AP) — Arbutus Biopharma Corp. ABUS) on Wednesday reported a loss of $24.5 million in its first quarter.
Yahoo
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion in life sciences deal experience Strong financial position with cash, cash equivalents and marketable securities of $113M WARM
Finnhub
Arbutus Biopharma Corporation reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported revenue was USD 1.76 million compared to USD 1.53...